Amid signs of de-escalating Middle East tensions and strong earnings reports, global markets have shown resilience, with major indexes like the Nasdaq Composite and S&P 500 reaching record highs. In this environment of optimism, dividend stocks can offer a compelling investment opportunity by providing regular income streams alongside potential capital appreciation.
|
Name |
Dividend Yield |
Dividend Rating |
|
Yeni Gimat Gayrimenkul Yatirim Ortakligi (IBSE:YGGYO) |
3.10% |
★★★★★★ |
|
Toukei Computer (TSE:4746) |
3.87% |
★★★★★★ |
|
Telekom Austria (WBAG:TKA) |
4.29% |
★★★★★★ |
|
Swiss Re (SWX:SREN) |
4.80% |
★★★★★★ |
|
NCD (TSE:4783) |
4.59% |
★★★★★★ |
|
Guangxi LiuYao Group (SHSE:603368) |
4.48% |
★★★★★★ |
|
GakkyushaLtd (TSE:9769) |
4.57% |
★★★★★★ |
|
CREEK & RIVER (TSE:4763) |
3.70% |
★★★★★★ |
|
Binggrae (KOSE:A005180) |
4.40% |
★★★★★★ |
|
Banque Cantonale Vaudoise (SWX:BCVN) |
3.59% |
★★★★★★ |
Click here to see the full list of 500 stocks from our Top Global Dividend Stocks screener.
Let’s take a closer look at a couple of our picks from the screened companies.
Simply Wall St Dividend Rating: ★★★★★☆
Overview: Bank of Nanjing Co., Ltd. offers a range of financial products and services in China, with a market cap of CN¥142.30 billion.
Operations: Bank of Nanjing Co., Ltd. generates revenue through its diverse financial offerings within China.
Dividend Yield: 4.3%
Bank of Nanjing’s dividend yield is among the top 25% in the Chinese market, at 4.29%. Despite a volatile dividend history with significant annual drops, recent earnings growth of CNY 6.60 billion suggests improved financial health. The current payout ratio is a low 28.1%, indicating dividends are well covered by earnings and expected to remain sustainable over the next three years, with forecasted annual earnings growth of 8.49%.
Simply Wall St Dividend Rating: ★★★★★☆
Overview: Yifeng Pharmacy Chain Co., Ltd. operates in the retail business of pharmaceutical products in China, with a market cap of CN¥28.39 billion.
Operations: Yifeng Pharmacy Chain Co., Ltd. generates revenue primarily from its pharmaceutical retail operations in China.
Dividend Yield: 3.2%
Yifeng Pharmacy Chain’s dividend yield of 3.24% ranks in the top 25% of Chinese market payers, supported by a reasonable payout ratio of 51.9%, ensuring coverage by earnings. The cash payout ratio stands at a low 32.1%, indicating strong cash flow support for dividends despite an unstable and volatile dividend history over the past decade. Recent earnings growth to CNY 1,678.48 million further strengthens its capacity to maintain dividend payments.
Simply Wall St Dividend Rating: ★★★★★★
Overview: Da-Cin Construction Co., Ltd. operates in civil engineering and building construction across Taiwan, Singapore, Malaysia, and Vietnam with a market cap of NT$18.22 billion.
Operations: Da-Cin Construction Co., Ltd. generates revenue from its civil engineering and building construction activities in Taiwan, Singapore, Malaysia, and Vietnam.
Dividend Yield: 6.1%
Da-Cin Construction Ltd. offers a high dividend yield of 6.09%, placing it in the top 25% of Taiwanese market payers, with stable and growing dividends over the past decade. The payout ratio is a reasonable 70.7%, ensuring coverage by earnings, while a low cash payout ratio of 30% indicates strong cash flow support. Recent earnings growth to TWD 1.69 billion enhances its ability to sustain dividend payments despite large one-off items affecting results.
-
Get an in-depth perspective on all 500 Top Global Dividend Stocks by using our screener here.
-
Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
-
Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SHSE:601009 SHSE:603939 and TWSE:2535.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com














